DIRS.INFO The most relevant business & tech news

☆ Dr. Fillit on Eli Lilly's Alzheimer's drug: Really having breakthroughs & success for the first time
▼ + stars: | 2024-06-11 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDr. Fillit on Eli Lilly's Alzheimer's drug: Really having breakthroughs & success for the first timeDr. Howard Fillit, Alzheimer’s Drug Discovery Foundation co-founder and chief science officer, joins 'Squawk Box' to discuss news of FDA panel's approval of Eli Lilly's Alzheimer's drug Donanemab, the future of Alzheimer's treatments, and more.

Persons: Fillit, Eli Lilly's Alzheimer's, Howard Fillit, Eli Lilly's Organizations: Discovery Foundation, FDA

☆ Here's an undervalued stock that can benefit from new Alzheimer's drugs
▼ + stars: | 2024-06-11 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Financials, Morgan Stanley, Wells, —, Jim, Eli Lilly, Biogen, Jim Cramer's, LLY, DOV Organizations: CNBC, Federal, GE Healthcare, FDA, GE, JPMorgan, Dover Locations: That's, Dover

☆ Apple jumps to a new high after AI unveil — plus, our latest thinking on 6 more portfolio stocks
▼ + stars: | 2024-06-11 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. "Notice where Stanley Black & Decker is when you have a good day for the bonds," Jim Cramer pointed out. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, you'll, Stanley Black, Decker, Dupont, Ed Breen, Jim, Eli Lilly, Eli Lilly Alzheimer's, Banks, Wells, Michael Santomassimo, Santomassimo, Morgan Chittum, We've, Tom Jorden, Coterra, Jorden, Jerome Powell, Jim Cramer's Organizations: CNBC, Longtime, Apple, Treasury, Club, DuPont, GE Healthcare, Huntington, Investing Club, Coterra Energy, Broadcom, VMware, Jim Cramer's Charitable

☆ Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug
▼ + stars: | 2024-06-11 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Tuesday explained why he continues to be bullish about pharmaceutical giant Eli Lilly . Continually confident about Eli Lilly because of the enormous success of its weight loss and diabetes drugs, he said the company's new Alzheimer's treatment has the potential to further boost business. On Monday, a panel of advisors to the Food and Drug Administration unanimously recommended Eli Lilly's Alzheimer's drug, currently known as donanemab. "I think this advisory committee decision on their Alzheimer's drug does precisely that." Eli Lilly did not immediately respond to request for comment.

Persons: CNBC's Jim Cramer, Eli Lilly, Eli Lilly's, it's, Cramer, they've Organizations: Food and Drug Administration, FDA Locations: U.S, Biogen

☆ A successful Alzheimer's drug will help Eli Lilly join the $1 trillion club
▼ + stars: | 2024-06-11 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Eli Lilly became the most valuable health-care company in the world on the back of its blockbuster diabetes and obesity drugs. The billions of dollars in Eli Lilly is investing in manufacturing capacity support the idea that the long-term opportunity is immense. Adding Eli Lilly to the market could help address some of the obstacles that limited Leqembi's sales early on. Eli Lilly, which has spent billions in search of a successful Alzheimer's treatment , had hoped for donanemab to be approved by now. A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana.

Persons: Eli Lilly, donanemab, Eli Lilly's, Donanemab, Leqembi —, Biogen, —, Jim Cramer's, Ken Langone, Morgan Stanley, Cantor Fitzgerald, Leqembi, Jim Cramer, Jim, Scott Olson Organizations: Food and Drug Administration, FactSet, Novo Nordisk, FDA, GE Healthcare, CNBC, Company, Getty Locations: GLP, Indianapolis , Indiana

☆ Eli Lilly may have developed the greatest drug of all time, says Jim Cramer
▼ + stars: | 2024-06-11 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly may have developed the greatest drug of all time, says Jim Cramer'Mad Money' host Jim Cramer breaks down Eli Lilly's success in pharmaceutical drugs and where the stock can go from here.

Persons: Eli Lilly, Jim Cramer, Eli Lilly's

☆ Eli Lilly's Alzheimer drug is 'a nice additional therapy', says Mizuho's Jared Holz
▼ + stars: | 2024-06-10 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly's Alzheimer drug is 'a nice additional therapy', says Mizuho's Jared HolzJared Holz, Mizuho Securities healthcare equity strategist, joins 'Squawk Box' to discuss the FDA's review of Eli Lilly's experimental Alzheimer drug, whether the drug is a game changer, and more.

Persons: Eli, Jared Holz Jared Holz, Eli Lilly's Organizations: Mizuho Securities Locations: Mizuho

☆ FDA advisers say Eli Lilly Alzheimer's treatment is effective
▼ + stars: | 2024-06-10 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA advisers say Eli Lilly Alzheimer's treatment is effectiveDr. Scott Gottlieb, Former FDA Commissioner, joins 'Closing Bell Overtime' to talk news that the FDA has deemed Eli Lilly's Alzheimers treatment as effective.

Persons: Eli Lilly Alzheimer's, Scott Gottlieb, Eli Lilly's Organizations: FDA

☆ FDA advisers say Eli Lilly's Alzheimer's treatment is effective
▼ + stars: | 2024-06-10 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA advisers say Eli Lilly's Alzheimer's treatment is effectiveCNBC's Angelica Peebles joins 'Closing Bell' to discuss the FDA's advisers vote on Eli Lilly's Alzheimer's drug.

Persons: Eli Lilly's, Angelica Peebles

☆ FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval
▼ + stars: | 2024-06-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. A panel of independent advisors to the Food and Drug Administration on Monday recommended Eli Lilly 's Alzheimer's drug donanemab, paving the way for the treatment to receive full approval in the U.S. later this year. If cleared for use, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the U.S. market after another treatment called Leqembi from Biogen and its Japanese partner Eisai. In a second vote, advisors unanimously said the benefits of Eli Lilly's donanemab outweigh its risks. It was another blow to Eli Lilly, which initially expected donanameb to win approval at the end of last year.

Persons: Eli Lilly, Eli Lilly's donanemab, Eisai, Eli Lilly's, Sarah Dolan, Dolan, Mark Mintun, donanameb, Leerink, David Risinger, Risinger Organizations: Food and Drug Administration, FDA Locations: Indianapolis , Indiana, U.S, Biogen, Black

☆ 15 little-known secrets you probably didn't know about Magic Kingdom
▼ + stars: | 2024-06-09 | by ( Jenna Clark | ) www.businessinsider.com time to read: +7 min

Here are some little-known secrets even the biggest Disney fans might not know about Magic Kingdom. There's a hidden homage to Walt Disney at the front of the parkWalt Disney Was born in 1901. Kim Renfro/INSIDERAlthough Space Mountain is an iconic attraction that has become synonymous with the park, it was not an opening-day attraction at Magic Kingdom in 1971. There are locations in both Disneyland and Disney World, and the Magic Kingdom Club 33 is located at the entrance to Adventureland near the Adventureland Bazaar. The Walt Disney World Railroad spans 1.5 miles across the parkMagic Kingdom's 20-minute train ride stops on Main Street, in Frontierland, and in Fantasyland.

Persons: —, Walt Disney, Jenna Clark, Walt, isn't, Roberto Machado Noa, it's, Jenna Clark Gaston's, It's, Kim Renfro, Mickey Mouse's, Mickey, Mickey Mouse, ROBERT SULLIVAN, who've, Walter E, Lilly Belle, Walt's, Lillian, Roy O, Roger E, Jenna Clark Just Organizations: Service, Disney, Magic, Business, Walt, Kingdom, Barber, Getty, Magic Kingdom, Kingdom's, Adventureland, Cinderella, Walt Disney World Railroad, Liberty, Hollywood Studios Locations: aren't, Frotierland, USA, New Fantasyland, Tomorrowland, Magic, Pinocchio's, Adventureland, There's, AFP, Frontierland, Fantasyland

☆ Jim Cramer's week ahead: Fed meeting and CPI report
▼ + stars: | 2024-06-07 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Friday guided investors through next week's most market-moving events, highlighting the Federal Reserve's meeting and the latest consumer price index report. Nvidia will implement its 10-for-1 stock split, and Cramer said shares might drop on Monday as buyers take profits. Oracle reports on Tuesday, and Cramer said he's not sure how this enterprise software company will fare. Casey's General Stores will also report that day, and Cramer said business is strong and the stock has been "a total winner." In that vein, the Fed will likely leave rates higher for longer at its Wednesday meeting, Cramer said.

Persons: CNBC's Jim Cramer, Jay Powell, Eli Lilly, Cramer, Eli Lilly's, he's, hasn't, nonfarm, He'll Organizations: Nvidia, Apple, Apple's, Conference, Vision Pro, FDA, Oracle, Casey's, Broadcom, Signet, Adobe Locations: Figma

☆ Fed rate cut guessing game dominates ahead of 5 major events for investors
▼ + stars: | 2024-06-07 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

Market wrap : Stocks were mixed and drifting in Friday afternoon trading. Wall Street's earlier gains Friday came despite a surge in bond yields and another pushout of Federal Reserve interest rate cut odds. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Morgan Stanley, Friday's, Eli Lilly, Lilly, Jim Cramer's, Jim Organizations: CNBC, Nasdaq, Abbott Laboratories, Nvidia, Apple, Developers, FDA, Broadcom, Jim Cramer's Charitable Locations: Wells

☆ Alphabet's new CFO was in the middle of the GLP-1 boom. Now she's onto generative AI
▼ + stars: | 2024-06-06 | by ( Jennifer Elias | ) www.cnbc.com time to read: +10 min

Alphabet announced on Wednesday that Eli Lilly Chief Financial Officer Anat Ashkenazi will be its new CFO after an almost year-long search. Shares of Eli Lilly have soared 90% in the past year and are trading at a record. When she joined Eli Lilly in 2001, she came in through the company's new venture capital division, which was co-founded by her then-spouse Ron Laufer. Fastest growth in decadesFounded in 1876, Eli Lilly has long been one of the major U.S. pharmaceutical companies. But the last couple years have marked a period of historic growth for Eli Lilly due to the exploding popularity of GLP-1s.

Persons: Anat Ashkenazi, Eli Lilly Eli Lilly Alphabet's, Ruth Porat, Eli Lilly, Ashkenazi, it's, Eli Lilly's, David Ricks, Morgan Stanley, Sundar Pichai, Hollie Adams, Ron Laufer, John Smiley, Eli, It's, Trump, Eli Lilly's Covid, we're, Askhenazi, OpenAI's, Larry Page, Sergey Brin, CNBC's Eric Rosenbaum, Toby Lyles Organizations: San, San Francisco Bay Area, Google, Economic, Bloomberg, Getty, CNBC, Tel Aviv University, Hebrew University, U.S . Food, Drug, U.S . Department of Justice, FDA, Reuters, Employees, NBC Locations: U.S, Indiana, San Francisco Bay, Davos, Switzerland, Israel, biopharma, North Carolina, Germany, New Jersey

☆ Shoppers are hyper-focused on ‘value.’ That doesn’t mean buying the cheapest option
▼ + stars: | 2024-06-06 | by ( Parija Bhatnagar | Parija Kavilanz | ) edition.cnn.com time to read: +5 min

Bargain retailers like Walmart and Costco have benefitted, as shown by the retailing industry’s recent slew of first-quarter earnings releases. Sales at its stores open at least a year increased 3.8% in the quarter from the same time last year. Which means that Americans are still spending, but selectively, and that “value shopping” means different things to different people. “A sizable segment of them are focused on value, however, that doesn’t directly correlate to a low price. Shoppers are willing to spend if they see value in an on-trend, well-made dress from Abercrombie – or a healthy salad from Sweetgreen.”

Persons: They’ve, What’s, ”, Neil Saunders, ” Saunders, Fitch, Stephanie Keith, Lilly Pulitzer, Laura Alber, Anne Hathaway, Della Patria, Elisabetta Villa, Richard Dickson, Zak Stambor, eMarketer, ” Stambor, “, Abercrombie – Organizations: New, New York CNN, Walmart, Costco, GlobalData, CNN, Abercrombie, Bloomberg, Getty, Hollister, Sonoma, Navy, Banana, “, Shoppers Locations: New York, Sonoma, Elm, Williams, Rome, Italy, Europe, Banana Republic

☆ Why the market is in a holding pattern, plus updates on 3 key portfolio stocks
▼ + stars: | 2024-06-06 | by ( Zev Fima | ) www.cnbc.com time to read: +3 min

One up, one down: Club stock Eaton is is down, despite being added to Jefferies' "Franchise Picks" list on Thursday. Please remember that when people get extra shares they tend to sell them, not buy them, but ultimately split stocks do well. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Mason Morfit, ValueAct, Salesforce, Eaton, Jefferies, Jim, Eli Lilly, payrolls, Jim Cramer's, Justin Sullivan Organizations: CNBC, Food and Drug Administration, Nvidia, Tech, Jim Cramer's Charitable Locations: San Francisco

☆ Alphabet taps Eli Lilly's Anat Ashkenazi as new CFO
▼ + stars: | 2024-06-05 | by ( Rohan Goswami | In Rohangoswamicnbc | ) www.cnbc.com time to read: +2 min

Eli Lilly CFO Anat Ashkenazi will become Alphabet's new chief financial officer effective July 31, Google's parent company announced Tuesday, almost a year after Alphabet first announced current CFO Ruth Porat would move to a new role as president and chief investment officer. Ashkenazi has had a 23-year career at Eli Lilly, which in a separate release confirmed her departure. Ashkenazi joined Eli Lilly in 2001 and had been CFO since 2021. She previously served as a CFO for several of the company's global business areas, helping to manage the revenue windfall from Eli Lilly's weight loss and diabetes drugs. Porat had nearly three-decade career as as an investment banker at Morgan Stanley, culminating as its CFO, before joining Google in 2015.

Persons: Eli Lilly, Anat Ashkenazi, Ruth Porat, Ashkenazi, Sundar Pichai, Eli Lilly's, Porat, Morgan Stanley, Philipp Schindler, Prabhakar Raghavan, Thomas Kurian, Susan Wojcicki, Robert Kyncl, Geoffrey Hinton, — CNBC's Jenn Elias, Annika Kim Constantino Organizations: Google, CNBC, YouTube

☆ Here's why Cramer says Ford stock must be 'bought aggressively' on the dip
▼ + stars: | 2024-06-05 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Persons: Jim Cramer, Ford, Jim, Eli Lilly, Anat Ashkenazi, Ashkenazi, shakeup, isn't, Jim Cramer's Organizations: CNBC, Federal Reserve, Nasdaq, Nvidia, Apple, Microsoft

☆ Eli Lilly's Wegovy rival Zepbound will help make weight-loss drug market worth $130 billion by 2030, Goldman Sachs says
▼ + stars: | 2024-06-02 | by ( George Glover | ) www.businessinsider.com time to read: +1 min

The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs said. New products such as Eli Lilly's Zepbound prompted the bank to raise its forecast. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . AdvertisementThe market for weight-loss drugs such as Ozempic and Wegovy will keep surging due to new products including Eli Lilly's Zepbound, according to Goldman Sachs. In a research note the bank forecast that the sector will be worth $130 billion by 2030 — $30 billion higher than its previous projection.

Persons: Goldman Sachs, Eli Lilly's Zepbound, —, Wegovy, Eli Lilly, Chris Shibutani Organizations: FDA, pharma, Service, Nordisk, Business Locations: Danish

☆ Cramer's Lighting Round: 'You've got a winner' with Astra Zeneca
▼ + stars: | 2024-05-31 | by ( Julie Coleman | ) www.cnbc.com time to read: 1 min

Viking Therapeutics : "I say you need to be in Eli Lilly. Step your game up, partner." AstraZeneca : "This is an amazing team that they've got at AstraZeneca now, and they've got fantastic formulations in oncology, but also heart. And they have a GLP-1 kind of thing going on, but it's a little far removed...You've got a winner with AstraZeneca."

Persons: Eli Lilly, they've, You've Organizations: Viking Therapeutics, AstraZeneca

☆ Here are the portfolio's top 5 performing stocks since April's Monthly Meeting
▼ + stars: | 2024-05-30 | by ( Morgan Chittum | ) www.cnbc.com time to read: +7 min

The latter fact is on display in our list of top-five performing portfolio stocks since the April 24 close through Wednesday's close, the eve of our May meeting. The chipmaker jumped 44.1% since April's Monthly Meeting. 4, Eli Lilly stock jumped 10.8% since our April 24 meeting. A slew of promising AI announcements helped fuel the stock's strong performance since the April meeting. More broadly, Broadcom has been one of the portfolio's biggest beneficiaries of the AI trade.

Persons: Dow, Jim Cramer, we're, Jim, Costco, Eli Lilly's, Eli Lilly, Jim Cramer's, Spencer Platt Organizations: Nasdaq, Dow Jones Industrial, Nvidia, Apple, China Academy of Information, Communications Technology, iPhone, Bank of America, Costco, Costco Wholesale, Walmart, Club, Broadcom, CNBC, Traders, New York Stock Exchange, Getty Locations: Wednesday's, China, U.S, Google's, New York City

☆ Calls Of The Day: Eli Lilly, UnitedHealth Group, Abbott Labs and Johnson & Johnson
▼ + stars: | 2024-05-30 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCalls Of The Day: Eli Lilly, UnitedHealth Group, Abbott Labs and Johnson & JohnsonThe Investment Committee discuss the latest Calls of the Day.

Persons: Eli Lilly Organizations: UnitedHealth, Abbott Labs, Johnson, Investment

☆ Here are Thursday's biggest analyst calls: Apple, Nvidia, Salesforce, Amazon, Okta, Eli Lilly, Cava, PayPal & more
▼ + stars: | 2024-05-30 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Goldman Sachs initiates Abbott Labs as buy Goldman said Abbott is well positioned for growth. UBS reiterates Apple as neutral UBS said its checks show iPhone pressure remains in China and the U.S. for Apple. Goldman Sachs reiterates Eli Lilly as neutral Goldman raised its price target on Eli Lilly to $785 per share from $740. Goldman Sachs reiterates Salesforce as buy Goldman said it's sticking with the stock following earnings on Wednesday. Goldman Sachs initiates AstraZeneca, Novartis and Novo Nordisk as buy Goldman initiated several biotech company's on Thursday and says it sees "innovation momentum a key focus."

Persons: Baird, OKTA, Goldman Sachs, Abbott, Goldman, Piper Sandler downgrades Cava, Piper, Eli Lilly, Wells Fargo, Wells, Mizuho, Wedbush, Daiwa, Stifel, it's, Salesforce, CRM's, Redburn, Guggenheim, Generac Organizations: UBS, Apple, Mizuho, PayPal, Bank of America, Gross, Amicus, USM, First, Deutsche Bank, Deutsche, JPMorgan, Nvidia, Technology, Northland, AstraZeneca, Novartis, Novo Nordisk, of America, TAM, Guggenheim Locations: China, Corning, Northland, 4Q24

Here's a rapid-fire update on all 33 stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. Below $200 a share is the level we'd get interested in buying more Salesforce stock, Jim said. The industrial name will continue to be a beneficiary of the AI trade due to Eaton's booming data center business. Alphabet : If this mega-cap name experiences a move lower, investors should scoop up shares, Jim said. Nvidia : There's not much more to say about Nvidia in light of another blowout earnings report and the strong guidance accompanying it.

Persons: Jim Cramer's, Jim, Apple's, Goldman Sachs, Salesforce, We've, Danaher, he'd, Walt Disney, We're, Estee Lauder, Eaton, Ford, Motors, Mary Dillon's, It's, Linde, Eli Lilly, Mark Zuckerberg's, Morgan Stanley, we're, Stanley Black, we've, Wynn, Jim Cramer, Michael M Organizations: Jim Cramer's Charitable Trust, CNBC, Club, Apple, Abbott Laboratories, Abbott Labs, Amazon Web Services, Broadcom, Dell, Samsung, Costco Wholesale, Coterra Energy, DuPont De Nemours, DuPont, The, Eaton, Ford, GE Healthcare, Honeywell, Jim, Linde, Microsoft, Nvidia, Palo Alto Networks, Palo Alto, Change, Procter & Gamble, Constellation Brands, Constellation, Modelo, Corona, Federal Reserve, TJX, Marshalls, Wynn Resorts, Jim Cramer's Charitable, Traders, New York Stock Exchange, Santiago, Getty Locations: China, Dover, Eaton, U.S, Maxx, HomeGoods, Wells Fargo, Macau, New York City

☆ Goldman Sachs raises target on Eli Lilly: Here's why
▼ + stars: | 2024-05-30 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailGoldman Sachs raises target on Eli Lilly: Here's whyChris Shibutani, Goldman Sachs anlayst, joins 'Squawk on the Street' to discuss what gives the analyst the confidence Eli Lilly and Novo Nordisk can continue to perform, what happens to the anti-obesity industry in 2030, and how the market will evolve.

Persons: Goldman Sachs, Eli Lilly, Here's, Chris Shibutani, Goldman Sachs anlayst Organizations: Novo Nordisk

Search resuls for: "lilly"

25 mentions found